SCHEMBL14937606

SCHEMBL14937606

CN(C(=O)n1cnc(-c2cccc(OCc3ccccc3)c2)c1)C1CCN(Cc2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.51
LMNA P02545 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
DRD2 P14416 2/20 0.47
DRD4 P21917 1/20 0.47
DRD3 P35462 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
FAAH O00519 2/20 0.46
CES2 O00748 1/20 0.46
WNK1 Q9H4A3 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HTT P42858 1/20 0.45
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
SIGMAR1 Q99720 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL428100 0.92 WNK1 (0.53) KDM4ELMNAMEN1KMT2ADRD2
SCHEMBL424822 0.92 RAB9A (0.51) KDM4ELMNAMEN1KMT2AALOX15
SCHEMBL424816 0.90 DRD2 (0.57) DRD2DRD4DRD3FAAHCES2
SCHEMBL526198 0.89 FAAH (0.58) KDM4ELMNAMEN1KMT2AALOX15
SCHEMBL16439270 0.89 DRD2 (0.50) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL14937809 0.88 MCHR1 (0.44) KDM4ELMNAMEN1KMT2AALOX15
Bromide SCHEMBL17819160 0.88 DRD2 (0.49) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL17828654 0.88 FAAH (0.45) KDM4ELMNAMEN1KMT2AALOX15
SCHEMBL17819173 0.88 KDM4E (0.51) KDM4ELMNAMEN1KMT2AALOX15
Hydrochloric Acid SCHEMBL17819165 0.88 FAAH (0.45) MEN1KMT2ADRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2606035-B1 PROCES FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS BIAL - PORTELA & CA S A (PT) 2017-09-06 EP disclosed
US-9458111-B2 Process for the synthesis of substituted urea compounds BIAL—PORTELA & CA, S.A. (PT) 2016-10-04 US disclosed
US-9458111-B2 Process for the synthesis of substituted urea compounds BIAL—PORTELA & CA, S.A. (PT) 2016-10-04 US disclosed
US-9458111-B2 Process for the synthesis of substituted urea compounds BIAL—PORTELA & CA, S.A. (PT) 2016-10-04 US disclosed
US-20130123493-A1 PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2013-05-16 US disclosed
US-20130123493-A1 PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2013-05-16 US disclosed
US-20130123493-A1 PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123493-A1 PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS UTS2R, ARG1, PRMT1 KDM4E 667/4885LMNA 3564/4885MEN1 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.